Specifically targeting DCs to modulate CD4+ T cell responses may represent a promising approach to treat allergic asthma where an enhanced Th2 response frequently leads to IgE production (IL-4), eosinophilia (IL-5), mast cell activation (IL-9), and AHR (IL-13) (86, 87). This evidence concerns the gene AHR and Increased total eosinophil count.